Should a complete blood count with platelet count be obtained in a newborn whose mother has thrombocytopenia?

Recommendation for Neonatal Platelet Count in Maternal Thrombocytopenia

Yes, obtain a CBC with platelet count in neonates when maternal thrombocytopenia is autoimmune in etiology or when the maternal platelet count is less than 100 × 10³/μL. 1

Risk Stratification by Maternal Platelet Count

The decision to check neonatal platelets should be guided by the severity and etiology of maternal thrombocytopenia:

When to Check Neonatal Platelets:

• Maternal platelets <100 × 10³/μL: Check neonatal CBC

  • At maternal platelets <50 × 10³/μL, the relative risk of neonatal thrombocytopenia increases 4.6-fold, with severe neonatal thrombocytopenia risk increasing 7.8-fold 2
  • At maternal platelets <50 × 10³/μL, 18.18% of neonates develop thrombocytopenia 1

• Autoimmune thrombocytopenia (ITP): Always check neonatal CBC regardless of maternal count

  • Among mothers with ITP, 85% of neonates were thrombocytopenic and 74% had platelets <50 × 10³/μL 3
  • Strong correlation exists for thrombocytopenia among siblings, making prior affected pregnancy a key risk factor 3

• Suspected alloimmune thrombocytopenia: Check neonatal CBC

  • This represents the highest-risk scenario, where severe neonatal thrombocytopenia (<20 × 10³/μL) occurs almost exclusively 4
  • The only severely affected neonates with morbidity or mortality are those born to mothers with antiplatelet alloantibodies 4

When Checking May Not Be Necessary:

• Maternal platelets >100 × 10³/μL with gestational/incidental thrombocytopenia: Risk is extremely low
  • Only 0.11% of neonates develop thrombocytopenia when maternal count is 100-149 × 10³/μL 1
  • Maternal platelet counts >75 × 10³/μL are not associated with increased risk of neonatal thrombocytopenia 2

Important Clinical Context

The correlation between maternal and neonatal platelet counts is weak (Pearson r = 0.038) 1, meaning maternal count alone cannot predict neonatal status. However, the etiology matters significantly—autoimmune and alloimmune causes carry substantially higher risk than gestational thrombocytopenia.

Timing and Clinical Outcomes:

• Neonatal thrombocytopenia, when it occurs, is associated with increased NICU admission (85% vs 43.8%), antibiotic use, longer hospital stays, and higher mortality (15% vs 2.5%) 5
• Despite higher rates of thrombocytopenia in at-risk neonates, actual bleeding complications remain rare, and intracranial hemorrhage is uncommon outside of alloimmune cases 1, 4

Common Pitfall to Avoid:

Do not assume that normal maternal platelet counts exclude the possibility of fetal/neonatal alloimmune thrombocytopenia (FNAIT). Mothers with FNAIT typically have normal platelet counts themselves because the antibodies target paternal antigens present on fetal platelets but absent on maternal platelets 6. FNAIT should be suspected when neonatal platelets are <100 × 10³/μL without alternative explanation, particularly if intracranial hemorrhage is present 6.

In summary: Check neonatal platelets when maternal count is <100 × 10³/μL or when maternal thrombocytopenia is autoimmune, as these scenarios carry clinically significant risk requiring monitoring and potential intervention.